Recently, there has been great interest in combining positron emission tomography (PET) and magnetic resonance imaging (MRI), and a number of integrated scanners capable of simultaneous acquisition have been developed and successfully tested in small animal 1,2 and human 3 imaging.
These efforts are broad enough to deserve their own review, something beyond our scope here. Instead, in this article we will focus on potential applications, especially in the brain.
What can we learn if we use simultaneous PET and MRI to study the brain?
To answer, we will break this question into parts: Why combine the information provided by PET and MRI? Why acquire PET and MR data simultaneously? Why focus on neurological applications initially?
Answering the first question is straightforward. The complementary anatomical and functional information obtained from separately performed MRI and PET examinations have long been combined either by performing a parallel analysis or by using software co-registration techniques to merge the two data sets. However, one major assumption that has been made in these cases is that no changes in underlying conditions have occurred between the two studies; increasingly, investigators are recognizing that this is not the case, particularly when assessing a subject's mental state, which may change in a matter of seconds, but also in some diseases such as acute ischemic stroke where changes can occur in a matter of minutes. As we probe illnesses of the mind more thoroughly, the state of the mind and the state of the brain at any given instant become more relevant.
This leads to the second and more challenging question. The simultaneous acquisition of PET and MRI data would allow the temporal correlation of these signals. Assessment of a number of diseases could benefit from simultaneous PET/MRI: quantitative measurements of brain cancer, neurodegenerative diseases, acute and chronic stroke, including stroke recovery, breast cancer, pelvic malignancies, cardiac imaging, etc. Identifying which of these many applications will be the first to have widespread clinical impact is an exercise in predicting the future-always a difficult task.
Perhaps more importantly, we might more profitably first discuss the fundamental measurement approaches that simultaneous technology opens up. Once implemented and validated, these technical tools could significantly influence a wide range of applications and contribute to the acceptance and successful clinical impact of PET-MRI.
Finally, answering the third question of-why start with brain-is simple: the enormous global burden from neuropsychiatric illnesses is higher than the burden from any other disease category in the developed world. These tremendous unmet medical needs make the brain a logical place to begin investigation. Furthermore, the brain's favorable imaging characteristics (generally stationary, good size compared with the field of view, multiple intrinsic contrasts of both structure and function/metabolism, etc.) and the wealth of MRI methods that work well in the brain will facilitate these initial efforts. In the following, we first discuss some of the methodological opportunities in a combined scanner and then describe how these could benefit neurological applications, particularly focusing on brain cancer, Alzheimer's disease, and ischemic stroke.
Technologies Enabling New Science
Simultaneous acquisition immediately brings to mind the possibility of improving the performance of one instrument by using the information obtained from the other modality. For example, a number of corrections must be applied in PET to obtain a correct quantitative measure of the activity concentration in a specific voxel, and the accuracy of some of these corrections, in principle, could be improved by including the MR information. As we consider the combination of MR and PET data, from a technical perspective PET might initially appear to benefit more from the addition of simultaneous MR data. However, the temporal correspondence of PET signals might help us better understand a number of MR techniques in vivo. In the end, combined PET/MRI will likely be a more quantitative tool than the two methods alone, and a number of diseases may yield their secrets best to highly quantitative methods.
Here we describe three technical improvements made possible via simultaneous acquisition. 
Magnetic-resonance-assisted Motion Correction
Voluntary and involuntary movements (i.e. cardiac or respiratory motion) are difficult to avoid and lead to degradation (blurring) of PET images and, in more severe cases, to the introduction of artifacts. These effects become particularly relevant when a quantitative voxel-by-voxel analysis is performed, especially considering the recent improvements in the spatial resolution of PET scanners.
Improved motion correction could be very beneficial to PET, and an elegant solution presents itself in a combined PET-MRI instrument, where the MR could be used to provide motion tracking and replace an optical tracking system. With proper pulse sequence programming, MR data can be acquired continuously during the PET data acquisition and can be used to characterize the independent motion of each of the voxels of interest. An MR-based motion correction approach could be used in difficult situations, such as correcting for internal motion associated with respiratory or cardiac activity in whole-body applications. External markers can, at best, approximate the motion of organs assuming a rigid body transformation, while the MR data could be used to more accurately model the movement of the internal organs using non-rigid body transformations. In the case of neurological applications, efforts have been made to minimize these effects by using different techniques to restrain the head of the subject [4] [5] [6] or, alternatively, to correct based on the motion detected using external optical markers However, in addition to the challenges posed by the segmentation task, errors in the registration of PET and MRI data acquired separately have limited the accuracy of partial volume correction methods in the past.
The post hoc co-registration task is further complicated by at least two other factors. First, the higher spatial resolution achievable with state-of-the-art PET scanners allows one to dissect biological processes in more detail. Second, as PET tracers with higher specificity are developed, the available anatomical information is increasingly limited. These problems are eliminated in the case of an integrated system, where simultaneity guarantees spatial correlation. Ultimately, the anatomical information provided by the MRI can be used as prior information to regularize the PET images in statistical reconstruction algorithms.
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Image-based Arterial Input Function Estimation
The analysis of dynamic PET data using tracer compartment models allows the estimation of parameters of interest related to normal and pathological changes in tissue function or metabolism. However, accurate quantification requires an input function to these models 
Promising Initial Neurological Applications
The excellent soft-tissue contrast makes MRI superior to CT for providing morphological information for neurological applications. As a result of this, the majority of patients who receive a PET examination typically receive a MR scan as well as part of their routine care. In addition to providing the anatomical context for analyzing the PET data, a number of MR methods have been developed for assessing cerebral blood flow (CBF) and cerebral
The enormous global burden from neuropsychiatric illnesses is higher than the burden from any other disease category in the developed world.
blood volume (CBV), water diffusion, and metabolite concentrations. All of these advanced MR methods are available in the combined scanner and can be profitably combined with PET methods. In this section we will describe some of the more promising initial brain applications.
Brain Cancer
The most common primary brain tumor, glioblastoma (GBM), is a uniformly fatal tumor afflicting approximately 13,000 persons each year in the US. 14 Despite aggressive therapy with surgery, radiation, and cytotoxic chemotherapy, the median survival is nine to 12 months and fewer than 5% of patients survive for five or more years. There is a desperate need for new therapies in GBM patients and there are now emerging data suggesting that one class of therapies-anti-angiogenesis therapies that block vascular endothelial growth factor (VEGF) receptors-may be effective in brain cancer. 15 However, the mechanism of action of antiangiogenic agents in any cancer remains poorly understood.
A number of quantitative MR methods, ranging from MR spectroscopy to can be used to exclude other causes of dementia and, more importantly, to assess morphological changes and the integrity of neurons, fiber tracts, and neuronal circuits involved in memory processes. 27 These methods have proved useful not only in the early diagnosis of AD, but also in the differential diagnosis of AD from other dementias, and they have been proposed for assessing disease progression and therapy monitoring. 28 Obtaining these data in a single imaging session is a major convenience, an issue particularly important in these often elderly and fragile patients. We note the complete commercial success of PET/CT over PET alone, suggesting that the benefit from ease of patient scheduling is substantial, a benefit previously considered modest.
The quantitative analysis of FDG uptake or PIB binding would also be greatly improved using the methods described in the previous section.
For example, it was suggested that changes in FDG uptake do not reflect impaired glucose metabolism but rather brain atrophy. Partial volume correction of the PET data based on the MR information would clarify this issue. Very often, long studies (e.g. 60-90 minutes) are performed and the quality of the data is compromised by motion; this could potentially be addressed in a combined scanner, as described above. Understanding the progression of pathological changes (e.g. amyloid deposition) in AD will require longitudinal studies. Ideally, these studies would be quantitative, reproducible, and minimally invasive, hence the need for an MR-based estimate of the AIF. A more reliable method to evaluate AD patients would in turn reduce the number of subjects required to answer a specific question. This could be particularly important now that treatments for AD are beginning to evolve, and combined measurements could be useful for patient selection (e.g. select mild cognitively impaired subjects that are likely to progress to AD) and monitoring treatment efficiency.
Ischemic Stroke
Stroke is the third leading cause of death in the US and the leading cause of adult disability. The majority (85%) of the 780,000 stroke cases 
Conclusions
There 
